Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition
نویسندگان
چکیده
منابع مشابه
Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
OBJECTIVE Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors lower low-density lipoprotein (LDL) cholesterol in the vast majority of patients with autosomal dominant familial hypercholesterolemia. Will PCSK9 inhibition with monoclonal antibodies, in particular alirocumab, be of therapeutic value for patients with autosomal recessive hypercholesterolemia (ARH)? APPROACH AND RESUL...
متن کاملInhibition of proprotein convertase subtilisin/kexin type 9 in the treatment of hypercholesterolemia.
Según datos de la Organización Mundial de la Salud, la enfermedad cardiovascular de origen isquémico o arterioscleroso (ECVA) es la primera causa de muerte en el mundo y especialmente en los países desarrollados. La aterosclerosis es una enfermedad arterial multifactorial, en la que el depósito en el espacio subendotelial de las lipoproteínas que transportan apolipoproteína B y colesterol, prin...
متن کاملFrom proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.
Statins are recommended as first-line therapy for patients with hypercholesterolaemia. A sizable proportion of patients, however, does not reach therapeutic goals, is statin intolerant, or, despite optimal statin therapy, is at high risk of ischaemic events. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a major role in lipid metabolism and several comorbidities. Monoclonal antibod...
متن کاملStatins, plasma proprotein convertase subtilisin/kexin type 9 concentrations, and LDL lowering.
The discovery in 2003 that variants in the PCSK9 (proprotein convertase subtilisin/kexin type 9) gene cause autosomal dominant hypercholesterolemia revealed a new aspect of LDL cholesterol (LDL-C) metabolism (1). PCSK9, a protein of 692 amino acid residues produced at high concentrations in the liver, kidney, and intestine, has profound effects on LDL-C concentrations (2). Both gain-of-function...
متن کاملRosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial.
BACKGROUND Although statin therapy is known to increase concentrations of PCSK9, whether this effect is related to the magnitude of LDL reduction is uncertain. This study was undertaken to understand the extent of this effect and examine the relationship between PCSK9 and LDL cholesterol (LDL-C) reduction. METHODS We measured plasma PCSK9 concentrations by ELISA at baseline and at 1 year in 5...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation
سال: 2015
ISSN: 0009-7322,1524-4539
DOI: 10.1161/circulationaha.115.016080